Simulation of propagating EAS Cherenkov radiation over the ocean surface

We present computing results of the Cherenkov light propagation in air and water from extensive air showers developing over the ocean. Limits on zenith angles of the showers, at which the registration of flashes of reflected Cherenkov photons by the satellite-based detector TUS is possible, are analyzed with consideration for waves on the ocean surface.Comment: 10 pages, 2 figures, 1 table. This preprint corrects errors which appeared in the English version of the article published in Mosc. Univ. Phys. Bull., 2011, Vol. 66, No. 5, p. 478. The original russian text was published in Vest. Mosk. Univ. Fiz., 2011, No. 5, p. 6

Possibility of Using a Satellite-Based Detector for Recording Cherenkov Light from Ultrahigh-Energy Extensive Air Showers Penetrating into the Ocean Water

We have estimated the reflected component of Cherenkov radiation, which arises in developing of an extensive air shower with primary energy of 10^20 eV over the ocean surface. It has been shown that, under conditions of the TUS experiment, a flash of the reflected Cherenkov photons at the end of the fluorescence track can be identified in showers with zenith angles up to 20 degrees.Comment: 5 pages, 3 figures. This preprint corrects errors which appeared in the English version of the article published in Bull. Rus. Acad. Sci. Phys., 2011, Vol. 75, No. 3, p. 381. The original russian text was published in Izv. RAN. Ser. Fiz., 2011, Vol. 75, No. 3, p. 41

Long-term disease control in advanced renal cell cancer with brain metastases with pazopanib (case report and literature review)

We report the case of advanced clear cell renal cell carcinoma with brain, pulmonary, hepatic and bone metastases treated with pazopanib.We observed the complete response in brain metastases and stable extracranial disease after 4 years of the treatment. According to the literature review this is the first reported case of complete response to pazopanib in brain metastases in renal cell carcinoma

PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study

BACKGROUND: This randomised, double-blind study compared PF-05280014 (a trastuzumab biosimilar) with reference trastuzumab (Herceptin®) sourced from the European Union (trastuzumab-EU), when each was given with paclitaxel as first-line treatment for HER2-positive metastatic breast cancer. METHODS: Between 4 April 2014 and 22 January 2016, 707 participants were randomised 1:1 to receive intravenous PF-05280014 plus paclitaxel (PF-05280014 group; n = 352) or trastuzumab-EU plus paclitaxel (trastuzumab-EU group; n = 355). PF-05280014 or trastuzumab-EU was administered weekly (first dose 4 mg/kg, subsequent doses 2 mg/kg), with the option to change to a 3-weekly regimen (6 mg/kg) from Week 33. Treatment with PF-05280014 or trastuzumab-EU could continue until disease progression. Paclitaxel (starting dose 80 mg/m2 ) was administered on Days 1, 8 and 15 of 28-day cycles for at least six cycles or until maximal benefit of response. The primary endpoint was objective response rate (ORR), evaluating responses achieved by Week 25 and confirmed by Week 33, based on blinded central radiology review. RESULTS: The risk ratio for ORR was 0.940 (95% CI: 0.842–1.049). The 95% CI fell within the pre-specified equivalence margin of 0.80–1.25. ORR was 62.5% (95% CI: 57.2–67.6%) in the PF-05280014 group and 66.5% (95% CI: 61.3–71.4%) in the trastuzumab-EU group. As of data cut-off on 11 January 2017 (using data up to 378 days post-randomisation), there were no notable differences between groups in progression-free survival (median: 12.16 months in the PF-05280014 group vs. 12.06 months in the trastuzumab-EU group; 1-year rate: 54% vs. 51%) or overall survival (median: not reached in either group; 1-year rate: 89.31% vs. 87.36%). Safety outcomes and immunogenicity were similar between the treatment groups. CONCLUSION: When given as first-line treatment for HER2-positive metastatic breast cancer, PF-05280014 plus paclitaxel demonstrated equivalence to trastuzumab-EU plus paclitaxel in terms of ORR. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT0198967

Длительный контроль распространенного почечно-клеточного рака с метастазами в головной мозг на фоне терапии пазопанибом (клинический случай и обзор литературы)

We report the case of advanced clear cell renal cell carcinoma with brain, pulmonary, hepatic and bone metastases treated with pazopanib.We observed the complete response in brain metastases and stable extracranial disease after 4 years of the treatment. According to the literature review this is the first reported case of complete response to pazopanib in brain metastases in renal cell carcinoma.Представлен клинический случай, демонстрирующий длительный контроль распространенного светлоклеточного почечно-клеточного рака с метастазами в головной мозг, легкие, печень, кости при применении пазопаниба. Показано, что эффект сохраняется в течение 4 лет; наблюдается полный ответ в отношении метастазов в головной мозг при стабилизации экстракраниального метастатического процесса. Как показывает обзор литературы, наше наблюдение является первым опубликованным описанием случая полного ответа со стороны метастазов в головной мозг при применении пазопаниба